Zobrazeno 1 - 10
of 304
pro vyhledávání: '"Phase 1 trials"'
Publikováno v:
Trials, Vol 23, Iss 1, Pp 1-15 (2022)
Abstract Background Phase 1 drug trials are popular treatment options for patients with advanced disease, despite the greater levels of uncertainty associated with them. However, their meaning and consequences for patient-participants remains under-e
Externí odkaz:
https://doaj.org/article/1b4bdb5f2a4942f6ae562c8a0b7582ac
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
René Bernards
Publikováno v:
Molecular Oncology, Vol 17, Iss 3, Pp 382-383 (2023)
The advent of a new generation of targeted cancer drugs requires a radically different design of early clinical trials. Here, René Bernards discusses why new clinical trial designs are needed and what is being done to achieve this. Such innovative t
Externí odkaz:
https://doaj.org/article/d32eea358caa4ad9a1b94f0378c15e2f
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Betty Ferrell, Tami Borneman, Anna Cathy Williams, Angela Scardina, Patricia Fischer, Thomas J Smith
Publikováno v:
Asia-Pacific Journal of Oncology Nursing, Vol 7, Iss 3, Pp 243-249 (2020)
The purpose of this article is to describe the lessons learned in the course of a 5-year research study on a palliative care intervention for persons on a Phase 1 clinical trial. Patients who are participating in Phase 1 trials and the families who c
Externí odkaz:
https://doaj.org/article/8bd7180b21614f068155f0654358c180
Publikováno v:
Contemporary Clinical Trials Communications, Vol 4, Iss C, Pp 179-185 (2016)
Background: Clinical trials are critical to scientifically evaluate promising new therapies in oncology, but patient accrual to these studies is persistently low. Patient preference plays an important role in enrollment in these trials. We performed
Externí odkaz:
https://doaj.org/article/d53ac3fe6e8648258b5c5f58d5a31029
Publikováno v:
International Journal of Radiation Oncology*Biology*Physics. 112:22-29
Clinical trials are studies to test new treatments in humans. Typically, these treatments are evaluated over several phases to assess their safety and efficacy. Phase 1 trials are designed to evaluate the safety and tolerability of a new treatment, t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b1d1b444956df039a9f30c2c4747b12c
https://doi.org/10.1016/j.ijrobp.2021.07.1700
https://doi.org/10.1016/j.ijrobp.2021.07.1700
Autor:
Everardo D. Saad, Elisabeth Coart
Publikováno v:
Expert Review of Precision Medicine and Drug Development. 6:271-280
Introduction: Precision medicine is impacting clinical practice and drug development in oncology, promoting notable changes in the design of early-phase cancer trials. There is increasing pressure ...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b770ed90c26f88dc84aa907e0e697dd0
https://doi.org/10.1080/23808993.2021.1915693
https://doi.org/10.1080/23808993.2021.1915693
Autor:
Deirdre M Boucherie, Cristina Sampaio, Tiago Machado, Olivier Rascol, Gonçalo S Duarte, Patrícia R Faustino, Joaquim J. Ferreira
Publikováno v:
Journal of Parkinson's Disease
Background: A global overview of drug development programs in Parkinson’s disease over the last few decades is lacking, while such programs are challenging given the multifaceted and heterogeneous nature of the disease. Objective: To indirectly ass
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::55c97546518b971fb151039abacdeaf8
https://doi.org/10.3233/jpd-202184
https://doi.org/10.3233/jpd-202184
Autor:
Sultan Chowdhury, Christoph Martin Dehnhardt, Tao Sheng, Clint Young, Rainbow Kwan, Michael Scott Wilson, Jun Chen, Matthew Waldbrook, Dinah Misner, C. Lee Robinette, Rebecca M. Reese, Elaine Chang, Henry Verschoof, Tanja S. Zabka, Girish Bankar, Philippe Bergeron, Luis Sojo, Karen Nelkenbrecher, Daniel P. Sutherlin, Amy Kim, Ivan William Hemeon, Andrea Lindgren, Jae H. Chang, Alla Yurevna Zenova, Shaoyi Sun, Jonathan Maher, Shannon D. Shields, Jun Li, Daniel F. Ortwine, David H. Hackos, Zhiwei Xie, Thilo Focken, Charles J. Cohen, Richard T. Dean, Shannon Decker, Janette Mezeyova, Kuldip Khakh, Antonio G. DiPasquale, Chien-An Chen, Andrew D. White, Brian Safina, Jodie Pang, Qi Jia, Sophia Lin, Jean-Christophe Andrez, J. P. Johnson, Steven J. McKerrall
Publikováno v:
Journal of Medicinal Chemistry. 64:2953-2966
Nav1.7 is an extensively investigated target for pain with a strong genetic link in humans, yet in spite of this effort, it remains challenging to identify efficacious, selective, and safe inhibitors. Here, we disclose the discovery and preclinical p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1a8a9431d81bf8ca2eed0fbbfbb36905
https://doi.org/10.1021/acs.jmedchem.1c00049
https://doi.org/10.1021/acs.jmedchem.1c00049